Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma

Brian Hess(Washington University in St. Louis), Joseph Boni(Adc Therapeutics (Switzerland)), Anastasios Stathis(Princess Margaret Cancer Centre), Weiyun Z. Ai(City College of San Francisco), Sam Liao, David Ungar, William Townsend(University College Hospital), Lori Liao, Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Melhem Solh(Johns Hopkins Hospital), Xiaoyan Zhang(Tongji University), Lisa Khouri
The AAPS Journal
December 10, 2021
10.1208/s12248-021-00660-3
Cited by 13

Related Papers

Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
|Clinical Cancer Research|2017|562
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2021|428